Literature DB >> 3903070

Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study.

M B Bracken, M J Shepard, K G Hellenbrand, W F Collins, L S Leo, D F Freeman, F C Wagner, E S Flamm, H M Eisenberg, J H Goodman.   

Abstract

A multi-center double-blind randomized clinical trial was conducted by the National Acute Spinal Cord Injury Study Group to examine the efficacy of high-dose methylprednisolone (1000-mg bolus and 1000 mg daily thereafter for 10 days) compared with that of a standard dose (100-mg bolus and 100 mg daily for 10 days). No significant difference was observed in neurological recovery of motor function, pinprick response, or touch sensation 1 year after injury between the two treatment groups, after adjustment for other potentially confounding factors. Analyses that specifically took into account the patients' total steroid dose and relative weight confirmed the lack of a steroid treatment effect. The case fatality rate was 10.7% during the 1st year after injury, and this was not associated with the steroid treatment protocol or the patient's gender. Deaths did occur significantly more frequently among patients who were completely (15.3%) and partially (8.6%) plegic than among those who were paretic (2.5%, p = 0.0005), and among patients aged 50 years or older (38.6%, p = 0.0001).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3903070     DOI: 10.3171/jns.1985.63.5.0704

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  38 in total

1.  Methylprednisolone for acute spinal cord injury: not a standard of care.

Authors:  Herman Hugenholtz
Journal:  CMAJ       Date:  2003-04-29       Impact factor: 8.262

Review 2.  Transplantation of umbilical cord blood stem cells for treating spinal cord injury.

Authors:  Dong-Hyuk Park; Jeong-Hyun Lee; Cesario V Borlongan; Paul R Sanberg; Yong-Gu Chung; Tai-Hyoung Cho
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

Review 3.  Medical treatments of acute spinal cord injury.

Authors:  W Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

Review 4.  The challenge of recruitment for neurotherapeutic clinical trials in spinal cord injury.

Authors:  Andrew R Blight; Jane Hsieh; Armin Curt; James W Fawcett; James D Guest; Naomi Kleitman; Shekar N Kurpad; Brian K Kwon; Daniel P Lammertse; Norbert Weidner; John D Steeves
Journal:  Spinal Cord       Date:  2019-04-08       Impact factor: 2.772

Review 5.  Antioxidant therapies for acute spinal cord injury.

Authors:  Edward D Hall
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

6.  The incomplete picture of incomplete spinal cord injury.

Authors:  Robert E Ayer; Farbod Asgarzadie
Journal:  Transl Stroke Res       Date:  2011-11-12       Impact factor: 6.829

Review 7.  Neuroprotection and acute spinal cord injury: a reappraisal.

Authors:  Edward D Hall; Joe E Springer
Journal:  NeuroRx       Date:  2004-01

Review 8.  Modern Medical Management of Spinal Cord Injury.

Authors:  Michael Karsy; Gregory Hawryluk
Journal:  Curr Neurol Neurosci Rep       Date:  2019-07-30       Impact factor: 5.081

9.  Effects of Human Erythropoietin on Functional Outcome of Patients with Traumatic Cervical Cord Injury; A Pilot Randomized Clinical Trial.

Authors:  Ehsan Ali Alibai; Fahim Baghban; Majid Reza Farrokhi; Navideh Mohebali; Mohammad Hossein Ashraf
Journal:  Bull Emerg Trauma       Date:  2015-07

10.  Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery.

Authors:  Samir P Patel; David H Cox; Jenna L Gollihue; William M Bailey; Werner J Geldenhuys; John C Gensel; Patrick G Sullivan; Alexander G Rabchevsky
Journal:  Exp Neurol       Date:  2017-03-30       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.